Seer
GenomeWeb Top 40 up 4 Percent in January, Following Broader Upswing
SomaLogic, Exact Sciences, and Myriad paced the winners in January, while Olink, a new addition to the Top 40, led decliners.
JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Agilent, Roche, Seer, More
Highlights from the second day included Agilent's $725 million investment in nucleic acids manufacturing and Roche's development plans for an integrated mass spec platform.
Seer Q3 Revenues up 81 Percent, Beating Wall Street Estimate
The proteomics firm posted revenues of $4.0 million, up from $2.2 million in the year-ago period and above the consensus Wall Street estimate of $3.5 million.
GenomeWeb Top 40 Declines 9 Percent in September, Marking Second Consecutive Down Month
The Dow Jones Industrial Average was down 9 percent, the Nasdaq was down 11 percent, and the Nasdaq Biotech Index was down around 2 percent.
JP Morgan Downgrades Seer to Neutral
A bank analyst said that "lengthened sales cycles from COVID and macroeconomic headwinds" presented challenges that will persist into the second half of the year.